216 filings
6-K
IFRX
InflaRx N.V.
21 Mar 24
Corporate Presentation March 2024
5:00pm
20-F
2023 FY
IFRX
InflaRx N.V.
Annual report (foreign)
21 Mar 24
7:28am
6-K
IFRX
InflaRx N.V.
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
SC 13G/A
IFRX
InflaRx N.V.
14 Feb 24
InflaRx / TANG CAPITAL PARTNERS ownership change
4:00pm
6-K
IFRX
InflaRx N.V.
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
tqkw4tzlz
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
vwip a87tviytzku
6 Nov 23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
8:00am
6-K
6sy53x1b
1 Nov 23
Current report (foreign)
8:04am
6-K
krfs27f91i3e
11 Sep 23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
8:45am
6-K
ewu wrp0fe4jksh42
30 Aug 23
Current report (foreign)
8:00am
6-K
8hj368ou0lpjb
10 Aug 23
Report of Foreign Private Issuer
8:00am
EFFECT
p3auhcni
12 Jul 23
Notice of effectiveness
12:15am
424B5
nxuayhtin4g
12 Jul 23
Prospectus supplement for primary offering
12:00am
CORRESP
m991j23
7 Jul 23
Correspondence with SEC
12:00am
UPLOAD
ael3x soy66
6 Jul 23
Letter from SEC
12:00am
F-3
jiw9hba mk3biqtuyf
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
lw7gr1sdx89cf40 2y
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
6-K
gjnf6
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
t6pulv
11 May 23
Current report (foreign)
8:00am
6-K
u6w8xse 1sc3eet5md5j
27 Apr 23
Current report (foreign)
4:01pm